Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Glenmark Specialty S.A. Clear all

Conditions: Advanced Solid Tumor, Lymphoma
Interventions: GRC 54276, GRC 54276 + Pembrolizumab, GRC 54276 + Atezolizumab; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Huntersville, North Carolina • Milwaukee, Wisconsin

Conditions: Perennial Allergic Rhinitis
Interventions: GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 34
States / cities: Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more

Conditions: Seasonal Allergic Rhinitis
Interventions: GSP 301 NS, Olopatadine HCl NS, Mometasone furoate NS, GSP 301 Placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 37
States / cities: Mission Viejo, California • San Diego, California • San Jose, California + 28 more

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GSP 301 Placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 32
States / cities: Mission Viejo, California • Ontario, California • Paramount, California + 26 more

Conditions: Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Interventions: GSP304 (tiotropium bromide) Inhalation Solution, GSP304 Placebo Inhalation Solution, Spiriva® Respimat® inhalation spray; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 25
States / cities: Andalusia, Alabama • Phoenix, Arizona • Tempe, Arizona + 18 more

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 43
States / cities: Mission Viejo, California • Orange, California • San Diego, California + 33 more

Search by objective public record fields.

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)